Reinach, Switzerland, 29 January 2013 – Evolva Holding SA (SIX: EVE) today announced that it has achieved a key milestone in its collaboration with BASF (announced in March 2011). The collaboration involves joint research on the design of novel and optimised biosynthetic routes for a natural product with crop protection potential.
Evolva has produced a yeast strain that achieves a fermentation yield that significantly exceeds the project requirement. Based on this achievement, BASF has made a low six-digit Swiss Franc milestone payment to Evolva.
Evolva will be entitled to receive royalties on sales of any future product, resulting from this collaboration.
About Evolva Holding SA
Evolva’s mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create and optimize small molecule compounds and their production routes. We are active in consumer healthcare and nutrition as well as in pharma. In both areas we have partnered projects as well as proprietary programs. For more information see www.evolva.com.
Neil Goldsmith, CEO Jakob Dynnes Hansen, CFO Paul Verbraeken, IR
email@example.com firstname.lastname@example.org email@example.com
+ 41 61 485 2005 + 41 61 485 2034 + 41 61 485 2035
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.